OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: DRUG: Combination of liposomal doxorubicin
Sponsor: Mridula George, MD